Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Arslan, T. Dogan, I. Akkurt, O. Ozdemir, M. E. Yildirim (Sivas, Turkey). Tumoural tissue specific promoter hypermethylation of distinct tumour suppressor genes in a case with nonsmall cell lung carcinoma: a case report. Eur Respir J 2009; 34: Suppl. 53, 2680

Member's Comments

No comment yet.

Related content which might interest you: Is caveolin-1 lost as a tumor suppressor gene in lung carcinoma? Source: Annual Congress 2004 - Lung development and cancer Year: 2004 Aberrant methylation of p16 tumour suppresor gene and DAP kinase in nonsmall cell lung carcinomas Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathological characteristics of primary non small cell lung carcinoma Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001 The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule Source: Annual Congress 2009 - Pathogenesis of lung cancer Year: 2009 Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement Source: Eur Respir J 2007; 30: 21-26 Year: 2007 p16INK4a promoter hypermethylation in tissue, blood, and sputum from non-small cell lung cancer and pulmonary inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 813s Year: 2006 An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Epigenetic inactivation of checkpoint kinase 2 gene in nonsmall cell lung cancer and its relationship with clinicopathological features Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Transcriptional regulation of the human osteopontin promoter in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 A rare involvement in a male patient with non-small cell lung carcinoma: breast metastasis Source: Eur Respir J 2005; 26: Suppl. 49, 538s Year: 2005 Mutant P53 expression in squamous cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002